• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Progesterone or Cerclage in Preterm Prevention in Women with Previous Preterm Birth and Short Cervix?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • A short cervix in women with previous preterm birth significantly raises the risk of recurrence by 3 fold
  • Conde-Agudelo et al. (AJOG 2018) compared the efficacy of vaginal progesterone and cerclage in prevention of preterm birth and adverse perinatal outcomes in this group of previous preterm birth and short cervix

METHODS:

  • Systematic Review and meta-analysis
    • Participants: Women with singleton gestation, previous spontaneous preterm birth and a second trimester short cervix (<25 mm) on ultrasound
    • Literary search included RCTs with a primary aim of preventing preterm birth in the above group
  • Daily dose of vaginal progesterone used in the trials varied from 90 to 200 mg, administered from 18–25 to 34–36 weeks of gestation
  • Trials used both McDonald and Shirodkar technique
  • Primary outcomes
    • Preterm birth <35 weeks of gestation
    • Perinatal mortality
  • Secondary outcomes
    • Preterm birth <37, <32, and <28 weeks of gestation
    • Respiratory distress syndrome and other adverse neonatal outcomes
    • Composite perinatal morbidity and mortality
  • Pooled relative risk (RRs) with 95% confidence intervals were calculated

RESULTS:

  • Five trials comparing vaginal progesterone vs placebo (265 women) and 5 comparing cerclage vs no cerclage (504 women) were included

Direct Comparisons

  • Vaginal progesterone, compared with placebo
    • Significantly reduced the risk of preterm birth <35 and <32 weeks of gestation, composite perinatal morbidity, mortality, neonatal sepsis, composite neonatal morbidity, and admission to the neonatal intensive care unit (RRs from 0.29 to 0.68)
  • Cerclage, compared with no cerclage
    • Significantly decreased the risk of preterm birth <35, <37, <32, and <28 weeks of gestation, composite perinatal morbidity/mortality, birthweight <1500 g (RRs from 0.64 to 0.70)
  • There were no differences in grade III/IV intraventricular hemorrhage, necrotizing enterocolitis, bronchopulmonary dysplasia, and birthweight <2500 g regardless of progesterone or cerclage

Indirect Comparison Between Cerclage and Progesterone

  • Adjusted indirect comparison meta-analyses showed no differences between vaginal progesterone and cerclage
    • Preventing preterm birth <35 weeks of gestation (RR, 0.97; 95% CI, 0.66–1.44; P =.93)
    • Perinatal death (RR, 0.97; 95% CI, 0.35–2.69; P =.96)
  • There were no differences in secondary outcomes

CONCLUSION:

  • Vaginal progesterone and cerclage are equally effective for the prevention of preterm birth in women with singleton pregnancies, previous preterm birth and short cervix
  • These findings agree with a previous, smaller RCT and Cochrane review comparing vaginal progesterone to cerclage that likewise did not show any difference in this population
  • There is data suggesting that there may be increased use of tocolysis and preterm PROM when using cerclage
  • Clinical implications of this study suggest either progesterone or cerclage may be used but further properly powered, large RCTs are required
    • In the interim, the data provided by this study may serve as the best evidenced based guide to care

Learn More – Primary Sources:

Vaginal progesterone is as effective as cervical cerclage to prevent preterm birth in women with a singleton gestation, previous spontaneous preterm birth, and a short cervix: updated indirect comparison meta-analysis

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Do Progestogens Prevent Preterm Birth in Symptomatic Pregnancies with a Short Cervix?
Does Vaginal Progesterone Improve Birth Outcomes for Mothers with Short Cervix?
Meta-analysis: Cerclage for Short Cervix but Without History of Preterm Birth 
Short Cervix and Risk for Preterm Birth: Do Pessaries Work? 

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site